WASHINGTON — An epinephrine nasal spray resulted in outcomes that were comparable with injections in pediatric patients, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
These findings indicate the spray’s potential as an effective alternative for treating severe allergic reactions in children, Sarina Tanimoto, MD, MBA, chief medical officer, ARS Pharma, and colleagues wrote.
Noting challenges and fears associated with epinephrine autoinjectors, the researchers said ARS Pharma’s neffy epinephrine nasal spray is